GPIHBP1 autoantibody is an independent risk factor for the recurrence of hypertriglyceridemia-induced acute pancreatitis

Background: GPIHBP1, a glycolipid-anchored protein of capillary endothelial cells, is a crucial part-ner for lipoprotein lipase (LPL) in plasma triglyceride metabolism. GPIHBP1 autoantibodies block LPL binding to GPIHBP1 and lead to severe hypertriglyceridemia (HTG) and HTG-induced acute pancreatitis (HTG-AP). We sought to define the incidence of GPIHBP1 autoantibodies in patients with HTG-AP. Objective: We determined the incidence of GPIHBP1 autoantibody in HTG-AP patients, and com-pared the clinical features and long-term outcomes between GPIHBP1 autoantibody-positive and nega-tive groups.Methods: An enzyme-linked immunosorbent assay was used to screen for GPIHBP1 autoantibody in 116 HTG-AP patients hospitalized from Jan 1, 2015 to Aug 31, 2019. All patients were followed up for 24 months. The primary outcome was the recurrence rate of HTG-AP during the two-year follow-up period. The incidence of recurrent episodes was analyzed by the Kaplan-Meier method and multivariable Cox regression was used to identify risk factors. Results: GPIHBP1 autoantibodies were present in 17 of 116 study patients (14.66%). The 2-year recurrence rate of HTG-AP was much higher in the GPIHBP1 autoantibody-positive group (35%, 6 in 17) than in the negative group (4%, 4 in 99). The multivariable Cox regression analysis showed that GPIHBP1 autoantibody was an independent risk factor for HTG-AP recurrence in two years. Conclusions: The presence of GPIHBP1 autoantibody is common in patients with HTG-AP, and is an independent risk factor for two-year recurrence of HTG-AP. (c) 2022 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Automated summary

This study determined the incidence of GPIHBP1 autoantibodies in patients with HTG-AP, and compared the clinical features and long-term outcomes between the GPIHBP1 autoantibody-positive and negative groups.